These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 9723312

  • 1. Disappearance of diabetes mellitus after conversion from FK 506 to Neoral in two liver transplanted patients.
    Lagget M, Marzano A, Actis GC, Leone N, Ciancio A, Salizzoni M, Rizzetto M.
    Transplant Proc; 1998 Aug; 30(5):1863-4. PubMed ID: 9723312
    [No Abstract] [Full Text] [Related]

  • 2. Tacrolimus to cyclosporine microemulsion formulation conversion in the pediatric liver transplant patient.
    Falkenstein K, Dunn S.
    Transplant Proc; 1998 Aug; 30(5):1964-6. PubMed ID: 9723354
    [No Abstract] [Full Text] [Related]

  • 3. Conversion from tacrolimus to microemulsion formulation of cyclosporine in pediatric liver transplantation.
    Alberti D, Reding R, Otte JB, Falchetti D, Rigamonti W, Caccia G, Sokal E, de Ville de Goyet J.
    Transplant Proc; 1998 Aug; 30(5):1858-60. PubMed ID: 9723310
    [No Abstract] [Full Text] [Related]

  • 4. Reduced acute rejection after liver transplantation with Neoral-based double immunosuppression.
    Reggiani P, Rossi G, Latham L, Caccamo L, Gatti S, Maggi U, Melada E, Paone G, Doglia M, Vannelli A, Fassati LR.
    Transplant Proc; 1998 Aug; 30(5):1855-6. PubMed ID: 9723308
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients.
    Melter M, Rodeck B, Kardorff R, Hoyer PF, Maibücher A, Brodehl J.
    Transplant Proc; 1996 Aug; 28(4):2276-8. PubMed ID: 8769224
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Low incidence of acute cellular rejection in liver transplantation with Neoral.
    Imventarza O, Lendoire J, Bianco G, Saúl J, Braslavsky G, Trigo P, Cueto G, Duek F, Aziz H.
    Transplant Proc; 1998 Aug; 30(5):1854. PubMed ID: 9723307
    [No Abstract] [Full Text] [Related]

  • 10. Neoral as the initial immunosuppressant in liver transplantation; conversion from Sandimmune to Neoral in stable patients.
    Kizilisik AT, al-Sebayel M, Ramirez CB.
    Transplant Proc; 1998 Nov; 30(7):3537-8. PubMed ID: 9838549
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Conversion to Neoral for tacrolimus-related adverse effects in liver transplant recipients and improvement in quality of life.
    Tolba RH, Wrigge B, Machein U, Minor T, Kalff JC, Hirner A, Wolff M.
    Transplant Proc; 2001 Nov; 33(7-8):3446-7. PubMed ID: 11750475
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.